Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL11485680 | 0.94 | KEAP1 (0.61) | KEAP1PDPK1AKR1C3GRM5MAPT | |
| SCHEMBL27580164 | 0.85 | KEAP1 (0.58) | KEAP1PDPK1GRM5MAPTALDH1A1 | |
| SCHEMBL9140155 | 0.85 | KEAP1 (0.58) | KEAP1PDPK1GRM5IKBKBCHUK | |
| SCHEMBL9141346 | 0.85 | KEAP1 (0.58) | KEAP1PDPK1AKR1C3GRM5MAPT | |
| SCHEMBL28796901 | 0.85 | KEAP1 (0.67) | KEAP1PDPK1GRM5MAPTIKBKB | |
| SCHEMBL9630618 | 0.83 | KEAP1 (0.49) | KEAP1PDPK1AKR1C3GRM5MAPT | |
| SCHEMBL28213845 | 0.83 | KEAP1 (0.55) | KEAP1PDPK1GRM5GAAHDAC8 | |
| SCHEMBL336234 | 0.82 | KEAP1 (1.00) | KEAP1PDPK1GRM5MAPTGAA | |
| SCHEMBL29696550 | 0.82 | KEAP1 (1.00) | KEAP1PDPK1GRM5MAPTGAA | |
| SCHEMBL9142182 | 0.82 | KEAP1 (0.54) | KEAP1PDPK1GRM5GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4221716-A | Intermediate and process for the preparation of 7-acylindolin-2-ones | A. H. ROBINS COMPANY, INC. (US) | 1980-09-09 | — | — | US | claimed |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| CN-119059958-A | Method for aryl debromination acylation of bromobenzazepine compounds | 上海沃凯生物技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-108003085-A | A kind of synthetic method of pharmaceutical intermediate sweet-smelling formacyl indole derivatives | 张开良 | 2018-05-08 | — | — | CN | disclosed |
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-5446162-A | Process for the production of 7-acylindoles | LONAZ LTD. (CH) | 1995-08-29 | — | — | US | disclosed |
| US-5380857-A | Process for the production of 7-acylindoles | LONZA LTD. (CH) | 1995-01-10 | — | — | US | disclosed |
| EP-0258048-B1 | 2-AMINO-3-AROYL-GAMMA-OXOBENZENEBUTANOIC ACIDS AND ESTERS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0181136-B1 | OXINDOLE ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4855448-A | ANTIINFLAMMATORY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-08 | — | — | US | disclosed |
| US-4855447-A | ANTIINFLAMMATORY, 7-AROYL-1H-INDOLE-3-PROPANOIC OR PROPANEDIOIC ACID INTERMEDIATES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-08 | — | — | US | disclosed |
| US-4782089-A | ANTIINFLAMMATORY, ANALGESIC | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0258048-A2 | 2-Amino-3-aroyl-gamma-oxobenzenebutanoic acids and esters | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4686224-A | Oxindole antiinflammatory agents | PFIZER INC. (US) | 1987-08-11 | — | — | US | disclosed |
| US-4644005-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1987-02-17 | — | — | US | disclosed |
| EP-0181136-A2 | Oxindole antiinflammatory agents | PFIZER INC. (US) | 1986-05-14 | — | — | EP | disclosed |
| US-4221716-A | Intermediate and process for the preparation of 7-acylindolin-2-ones | A. H. ROBINS COMPANY, INC. (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | KEAP1 707/4885PDPK1 2663/4885AKR1C3 436/4885 |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | IGF1R, INHA, CCNO | KEAP1 1122/4885PDPK1 1958/4885AKR1C3 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.